Thymoquinone Inhibits the CXCL12-Induced Chemotaxis of Multiple Myeloma Cells and Increases Their Susceptibility to Fas-Mediated Apoptosis
2011

Thymoquinone's Effects on Multiple Myeloma Cells

Sample size: 9 publication 10 minutes Evidence: moderate

Author Information

Author(s): Badr Gamal, Lefevre Eric A., Mohany Mohamed

Primary Institution: King Saud University, Riyadh, Saudi Arabia

Hypothesis

Thymoquinone inhibits the chemotaxis of multiple myeloma cells and increases their susceptibility to apoptosis.

Conclusion

Thymoquinone demonstrates potent anti-myeloma activity by inhibiting cell migration and enhancing apoptosis in multiple myeloma cells.

Supporting Evidence

  • Thymoquinone treatment significantly inhibited CXCL12-mediated chemotaxis in multiple myeloma cell lines.
  • TQ increased CD95 expression on multiple myeloma cells, enhancing their susceptibility to apoptosis.
  • Primary multiple myeloma cells showed a 74% reduction in migration towards CXCL12 after TQ treatment.
  • TQ did not affect the viability of healthy donor PBMCs while inhibiting MM cell migration.

Takeaway

Thymoquinone, a compound from black seed oil, helps fight a type of blood cancer by stopping cancer cells from moving and making them easier to kill.

Methodology

The study involved in vitro assays to assess the effects of thymoquinone on multiple myeloma cell lines and primary cells, including chemotaxis and apoptosis assays.

Limitations

The study primarily focused on in vitro models, which may not fully replicate in vivo conditions.

Participant Demographics

Patients with multiple myeloma provided bone marrow aspirate samples.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0023741

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication